Clinical trials: Colorectal Diseases
Colorectal Cancer Stage 0, Colorectal Cancer Stage I
Matrilysin Expression in Different Stages of Colorectal Tumors
Matrix metalloproteinases (MMPs) have been shown to be involved in cancer biology. Significant expression of MMP-7 (matrilysin) in colorectal cancer is mainly associated with metastatic disease even though it is expressed in most…
- Conditions
- Colorectal Cancer Stage 0, Colorectal Cancer Stage I, Colorectal Cancer Stage II, Colorectal Cancer Stage III
- Trial name
- MMP7 (NCT01570452)
- Testing
- colonic or colorectal resection
- Where
- Italy
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Primary Stage IV Hepatobiliary, Esophageal
Improving Goals of Care Discussion in Advanced Cancer Patients
The goal of this study is to increase and improve Goals of Care discussions for advanced cancer patients by training medical oncologists to conduct these discussions.
- Conditions
- Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma
- Trial name
- NCT02374255
- Testing
- GoC intervention
- Where
- 4 sites in United States
- Volunteers
- 265 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Colorectal Cancer, Head and Neck Cancer
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT00820417
- Testing
- Cetuximab/Gefitinib combination and/or monotherapy
- Where
- 2 sites in Belgium, Spain
- Volunteers
- 63 people
- Sponsor
- Harrison Clinical Research
Colon Cancer Metastatic
Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC
This study will enroll patients with metastatic colorectal cancer treated with the combination of Trifluridine/Tipiracile and Bevacizumab across 15 italian centers.
- Trial name
- FLOWER (NCT07494578)
- Testing
- Fluoropyrimidine
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rectal Neoplasms
Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients
The purpose of this study is to seek the proper dose of capecitabine in post-operative concurrent chemotherapy for stage II/III elderly rectal cancer patients receiving radical surgery, and evaluate the toleration of this…
- Trial name
- NCT01268943
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chinese Academy of Medical Sciences
Colorectal Cancer
SarCNU in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of sarCNU in treating patients who have recurrent or…
- Trial name
- NCT00028015
- Testing
- SarCNU
- Where
- 7 sites in Canada
- Volunteers
- 18 people
- Sponsor
- NCIC Clinical Trials Group
Rectal Cancer
Prediction of the Response to Neoadjuvant Radiation Chemotherapy Through Texture Analysis Derived From Medical Imaging
In patient with complete pathological response, surgery could be omitted without compromising progression-free or overall survival. A powerful prediction model is needed to guide management of this population.
- Trial name
- RECTOMICS (NCT04920435)
- Where
- 3 sites in France
- Volunteers
- 124 people
- Sponsor
- University Hospital, Brest
Breast Cancer, Stage 0, Colorectal Cancer Stage I
Virtual Rehabilitation for Cancer Survivors
Pragmatic hybrid type 1 effectiveness-implementation (E-I) trial of a virtual cancer rehabilitation program: The study team will conduct a multi-center hybrid type I effectiveness-implementation study to examine the clinical…
- Conditions
- Breast Cancer, Stage 0, Colorectal Cancer Stage I, Head and Neck Cancer Stage I, Lymphoma
- Trial name
- NCT05898789
- Testing
- CaRE@Home intervention
- Where
- Canada
- Volunteers
- 388 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer
Effect of Stent Placement on Short Term Survival of Left Sided Obstructive Colorectal Cancers
The aim of this observational study is to determine effect of stent placement on survival results in first three years in a patient who applied to the emergency department with obstruction due to colorectal cancer.
- Trial name
- NCT06437691
- Testing
- Self-Expandable Metallic Stent Placement
- Volunteers
- 65 people
- Sponsor
- Yasir Musa Kesgin, MD
Cancer, Lung Cancer
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Numerous studies have shown that even when imaging does not reveal the presence of cancer cells, traces of tumor DNA (i.e. originating from cancer cells) can be detected in the blood of certain patients: this is called molecular…
- Conditions
- Cancer, Lung Cancer, Colo-rectal Cancer, Pancreas Cancer
- Trial name
- UMBRELLA (NCT06332274)
- Testing
- Tislelizumab, Blood sampling
- Where
- France
- Volunteers
- 717 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Background: Metastatic colorectal cancer (mCRC) is cancer that has spread beyond the colon and rectum. Most people with mCRC die within 5 years. New immune-based treatments are making progress with some types of colon cancer.
- Conditions
- Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer
- Trial name
- NCT06603818
- Testing
- Tiragolumab, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Metastasis
Hepatic Artery Infusion With Oxaliplatin
Hepatic artery infusion (HAI) with oxaliplatin (OX), systemic 5 fluorouracil (5FU), and leucovorin (HAI/OX/FU) will be implemented using an interventional radiology technique to obviate the need for initial major surgery…
- Conditions
- Colorectal Cancer, Metastasis, Liver Cancer
- Trial name
- NCT00244348
- Testing
- Oxaliplatin (via HAI), 5 Fluorouracil (systemic)
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Colorectal Cancer Recurrent
Microbiome and Colorectal Cancer Recurrence
Anastomotic leak is associated with higher rates of tumor recurrence after colorectal cancer surgery. However, the mechanisms responsible remain unknown.
- Trial name
- NCT07057076
- Volunteers
- 51 people
- Sponsor
- Hospital del Mar
Colorectal Cancer
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Monotherapy treatment with CS-7017 to assess progression-free-survival (PFS) of subjects who achieved an objective response of Disease Control on first line therapy with Folinic acid (leucovorin), Fluorouracil (5-FU), Oxaliplatin…
- Trial name
- NCT00986440
- Testing
- CS-7017
- Where
- 39 sites in Czechia, France and 7 more
- Volunteers
- 84 people
- Sponsor
- Daiichi Sankyo
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with…
- Trial name
- NCT04793958
- Testing
- MRTX849, Cetuximab, mFOLFOX6 Regimen
- Where
- 419 sites in United States, Argentina and 30 more
- Volunteers
- 461 people
- Sponsor
- Mirati Therapeutics Inc.
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
- Trial name
- NCT07145255
- Testing
- ADC
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- MBrace Therapeutics
Anastomotic Leak, Rectal Cancer
Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing
Rationale: The surgical complication of intestinal anastomotic leak remains a clear and present danger to patients despite advances in surgical technique and ever more powerful antibiotics.
- Trial name
- SES-DTA (NCT02682485)
- Testing
- Cipro, metronidazole, neomycin combo, Serial Endoscopic Surveillance, Saline
- Sponsor
- University of Chicago
Metastatic Colorectal Cancer
Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer
This is a prospective, open, multicenter, randomized controlled phase II study designed to observe the difference of efficacy, adverse events and quality of life between second-line and third-line application of Fruquintinib in…
- Trial name
- NCT05447715
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Weijian Guo
Rectal Cancer
Diagnostic Value of Whole-Body MRI for Rectal Cancer Preoperative Staging
The purpose of this study is to determine whether whole-body MRI (WB-MRI) accuracy is superior to FDG-PET-CT considered as the gold-standard for the staging of distant lesions of rectal cancer.
- Trial name
- NCT01745874
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University of Lausanne Hospitals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.